Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The patients who have achieved LDL-C levels below the currently recommended targets may still
experience cardiovascular events. To reduce further the risk of coronary heart disease (CHD),
raising HDL-C and lowering TG may be the secondary therapeutic target. However, increased
HDL-C levels do not mean increase in functional HDL-C. It also remains controversial whether
functional HDL is more important than total circulating levels of HDL-C in reducing CHD.
Actually, the increased concentration of HDL alone might be ineffective indicating that
qualitative changes in HDL levels in response to drug interventions are required to result in
clinical benefit.
The investigators set up a clinical trial investigating effect of (rosuva)statin treatment on
functional HDL-C levels particularly in Asian populations, who have relatively low HDL-C.